Serge Saxonov - 02 Mar 2026 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
Chief Executive Officer, Director
Signature
/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov
Issuer symbol
TXG
Transactions as of
02 Mar 2026
Net transactions value
-$367,097
Form type
4
Filing time
04 Mar 2026, 16:14:12 UTC
Previous filing
02 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Saxonov Serge Chief Executive Officer, Director 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON /s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov 04 Mar 2026 0001786720

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Sale $323,985 -14,292 -1.2% $22.67 1,205,527 02 Mar 2026 Direct F1, F2
transaction TXG Class A Common Stock Sale $43,111 -1,860 -0.15% $23.18 1,203,667 02 Mar 2026 Direct F1, F3
transaction TXG Class A Common Stock Gift -2,750 -0.23% $0.000000* 1,200,917 03 Mar 2026 Direct
holding TXG Class A Common Stock 27 02 Mar 2026 See footnote F4
holding TXG Class A Common Stock 213,250 02 Mar 2026 See footnote F5
holding TXG Class A Common Stock 58,000 02 Mar 2026 See footnote F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
F2 This transaction was executed in multiple trades at prices ranging from $22.15 to $23.145, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $23.15 to $23.25, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F5 The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F6 The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.